AArtificial intelligence Read More Meta’s latest move in the AI talent war, plus Cramer’s 4 quick hitsJuly 17, 2026 Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…
HHealthcare Read More Johnson & Johnson (JNJ) Q2 earningsJuly 15, 2026 Johnson & Johnson beat Wall Street estimates for second-quarter sales and profit on Wednesday, as strong growth from…
EEconomy Read More Stock market today: Live updatesJuly 15, 2026 Traders work at the New York Stock Exchange on July 10, 2026. NYSE Stock futures rose early Wednesday…
HHealthcare Read More Johnson & Johnson has a chance to show it’s more than just a rotation winnerJuly 14, 2026 Johnson & Johnson shares have showed signs of life ahead of earnings. For the stock to keep running,…
PPersonal finance Read More 64 With $1.1 Million in a Traditional IRA. Yield Volatility Is Back. Here’s Where I’m Allocating CapitalJune 29, 2026 Quick Read JNJ and PG anchor a three-stock Dividend King allocation targeting tax-deferred income inside a $1.1M IRA…
HHealthcare Read More Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?June 28, 2026 Choosing between established healthcare giants often comes down to balancing income needs against growth potential. Both Bristol Myers…
AArtificial intelligence Read More The AI trade cooled and oil sank. A closer look at Wall Street’s volatile weekJune 27, 2026 Wall Street spent the week debating who the biggest winners and losers of the artificial intelligence boom will…
HHealthcare Read More We’re trimming a stock into strength, raising our price targetJune 25, 2026 We are selling 50 shares of Cardinal Health at roughly $235. Following the trade, Jim Cramer’s Charitable Trust…
AArtificial intelligence Read More Salesforce looks to strengthen its AI platform, a positive note for J&JJune 15, 2026 Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…
HHealth Read More RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limitedMay 31, 2026 More than one-third of responders with previously treated disease achieved complete responses, with median duration of response not…
PPersonal finance Read More Wes Moss’ $1.6 Million Portfolio Rule Quietly Beats Government Pensions for Affluent RetireesMay 20, 2026 Quick Read If a $50,000 pension is worth $1 million in bond-equivalent wealth, then a $1.6 million portfolio…
PPersonal finance Read More The Nationwide Social Security Survey Says Most Americans Are Flying Blind on Benefits, Here’s the Income Strategy That Fills the GapMay 10, 2026 Quick Read The Stocks: Johnson & Johnson (JNJ) has extended a 64-year streak of consecutive annual dividend increases…